|
|
Recent Articles
-
Albemarle Continues to Navigate a Low Lithium Price Environment
May 12, 2025
-
Image Source: TradingView.
Albemarle’s cash flow from operations in the quarter came in at $545 million, which included a $350 million customer prepayment. The firm reiterated its view that it has line of sight to breakeven free cash flow assuming current lithium pricing. Albemarle also maintained its full-year 2025 outlook considerations. At year-end 2024 average lithium market price of $9/kg LCE, net sales are targeted in the range of $4.9-$5.2 billion, with adjusted EBITDA in the range of $0.8-$1.0 billion. Though Albemarle continues to struggle with a low lithium price environment, we were encouraged by commentary regarding free cash flow, and the stock remains an idea in the ESG Newsletter portfolio.
-
Dividend Increases/Decreases for the Week of May 9
May 9, 2025
-
Let's take a look at firms raising/lowering their dividends this week.
-
Magnificent 7 Earnings Reports Not Bad Thus Far
May 6, 2025
-
Shortly after Trump's Liberation Day, where the President unveiled lofty tariffs on numerous countries, we released our wait-and-see outlook for the equity markets, which thus far has proven to be the right move, with the markets largely recovering from the depths reached in April. The S&P 500, for example, is down just 3.3% year-to-date, excluding dividends. A lot has happened since Liberation Day, including easing of tariffs to a 10% baseline for most, if not all, countries, with the key exception of China, where tariffs remain extremely elevated and prohibitive. Many countries are now reportedly negotiating trade agreements with the White House, and we expect China to be added to that list soon, even if a full US/China trade agreement won't be completed in the near term, as full-scale trade deals take time to mold. Thus far, we have been impressed by earnings this season, particularly by the Magnificent 7.
-
Vertex Raises Bottom End of 2025 Revenue Guidance Range
May 6, 2025
-
Image Source: Vertex Pharma.
Vertex’s reported results were impacted by an intangible asset impairment charge of $379 million associated with VX-264, but the company’s non-GAAP net income still fell to $1.1 billion in the first quarter compared to $1.2 billion in last year’s quarter as a result of higher operating expenses. Looking to the balance of 2025, however, Vertex raised the low end of its revenue guidance range to be between $11.85-$12 billion, up from $11.75-$12 billion previously. The company ended the quarter with $11.4 billion in cash and cash equivalents and no traditional debt. Though Vertex’s first quarter results came in lower than expected, we continue to like the long term story at the company, particularly in pain management, and the stock remains key biotech exposure in the Best Ideas Newsletter portfolio.
|
